Site Search
Professionals 257 results
- Yulia Makarova
- Partner of Winston & Strawn London LLP
- +44 20 7011 8803
- vCard
Partner of Winston & Strawn London LLP
Capabilities 79 results
Practice Area
Financial Innovation & Regulation
Winston’s Financial Innovation & Regulation attorneys routinely counsel financial services, digital assets, and other clients on complex banking, crypto, FinTech, consumer financial, and securities matters. Many of our team members previously held positions as in-house counsel at global financial institutions and served in positions at government agencies, which gives us considerable experience in helping our clients obtain innovative, effective, and efficient solutions.
Practice Area
Privacy: Regulated Personal Information (RPI)
Winston’s Regulated Personal Information (RPI) Practice offers seamlessly integrated counseling and litigation services to companies looking for practical and solution-oriented assistance navigating the compliance, regulatory, and private class action enforcement risks presented by the emerging patchwork of complex (and often conflicting) privacy laws in the United States and beyond.
Practice Area
Our attorneys have extensive experience counseling U.S. and multinational public companies across a range of industries in all aspects of corporate governance, securities, and compliance matters. We advise public companies, boards of directors and their committees, and senior executives on the corporate governance and compliance matters that public companies and their leadership confront—from board structuring and succession planning to shareholder activism and SEC regulation. Drawing on our experience as seasoned counselors, we keep clients abreast of evolving trends and best practices to proactively manage any governance or compliance issues. We have assembled one of the most experienced teams of any law firm in the country that’s counseling public companies.
Experience 12 results
Experience
|January 22, 2026
Advised SQM on US$600M offering of subordinated capital notes due 2056 (Hybrid Bond Offering)
Winston & Strawn LLP advised longstanding client Sociedad Química y Minera de Chile S.A. (“SQM”) (NYSE: SQM) on its US$600 million offering of subordinated capital notes. The notes were offered in the United States pursuant to Rule 144A and outside the United States pursuant to Regulation S.The subordinated capital notes are due in 2056 and constitute SQM’s first international hybrid bond issuance, structured to be consistent with SQM’s recent UF 10 million (approximately US$ 430 million) Series S hybrid-subordinated bond issuance in the Chilean securities market. The notes bear an initial annual interest rate of 5.625% and are subject to reset on April 22, 2031 (the “First Reset Date”), and on every fifth anniversary thereafter, based on a spread over the 5-year U.S. Treasury bond rate, with interest rate step-ups on the fifth and twentieth anniversaries of the First Reset Date. The transaction closed on January 22, 2026.BofA Securities, Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Santander US Capital Markets LLC, and Scotia Capital (USA) Inc. acted as initial purchasers of the notes.Link Capital Partners was financial advisor to SQM.SQM is a global company with a leading position in the lithium, iodine, and potassium nitrate markets. It develops and produces a diverse range of products for industries essential to human progress, including health, nutrition, renewable energy, and technology, driven by innovation and technological development.The Winston & Strawn team advising on the transaction included corporate partner Sey-Hyo Lee (New York) and foreign legal advisor Bruno M. Fiorino (New York). Partner Katherine Erbeznik (New York) advised on tax matters.
Experience
|September 22, 2025
Winston Paris advised the founders and shareholders of Bylaw, on its acquisition by Septeo
Founded in 2019 by Adrien Aboudaram and Tuan Ardouin, Bylaw has developed next-generation AI technology to automate the processing of legal and financial documents. With a team primarily dedicated to R&D, the legaltech company aims to become the leading AI reference for regulated professions.
Experience
|March 18, 2025
Winston Blunts Earnout Payment
Following a bench trial in Fall 2024, a New York trial court ruled in March 2025 that Cresco Labs, Inc. was not required to pay a US$45M earnout under a merger agreement. The court found that Cresco did not receive “commercially reasonable access” to New York’s adult-use cannabis market, which was supposed to be subject only to a non-competitive application or approval process. Adopting Cresco’s arguments, the court determined that only the Office of Cannabis Management and Cannabis Control Board could decide when and how applicants access the adult-use market. The court agreed that regulators required Cresco to pay a significant one-time fee, prioritized other applicants, and had broad discretion over approvals. This win supports claims that New York’s adult-use program lacks details and clear entry paths, frustrating industry leaders’ efforts to develop a robust adult-use market.
Insights & News 2,271 results
Webinar
|February 24, 2026
Venezuela in Transition: The Evolving Investment Landscape
Recent political developments in Venezuela are significantly impacting the country’s outlook, presenting novel challenges and opportunities for investment in the region.
Global Trade & Foreign Policy Insights
|February 24, 2026
|7 Min Read
U.S. Supreme Court Invalidates President Trump’s Emergency Tariffs
On February 20, 2026, the Supreme Court of the United States (SCOTUS) issued a landmark 6–3 decision sharply curtailing presidential authority to impose unilateral tariffs under the International Emergency Economic Powers Act (IEEPA).
Benefits Blast
|February 17, 2026
|9 Min Read
Recent developments at the federal legislative and regulatory levels signal a significant shift toward greater transparency requirements in the pharmacy benefit management (PBM) industry.
Other Results 106 results
Law Glossary
The FDA stands for the Food and Drug Administration. It is a federal agency charged with protecting the public by regulating the safety and security of drugs, biological products, veterinary medications, and medical devices. FDA responsibilities also cover the safety of: foods for U.S. consumers, cosmetics, animal feed, and radiation-emitting products. Various rules may be established and enforced by the agency in response to U.S. laws or presidential executive orders.
Law Glossary
What Is the Standard for the FDA to Grant a Biosimilar License?
Granting a Biosimilar License
Law Glossary
What Is the Standard for the FDA to Grant a Generic Drug License?
An Abbreviated New Drug Application (ANDA) must contain evidence that the proposed generic drug product is bioequivalent to the reference drug.